Meitav Investment House’s Protalix BioTherapeutics PLX Stock Holding History

Meitav Investment House’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-244,332	Closed	-$494K	–	544
2023 Q1	$494K	Sell	244,332 -150	-0.1%	-$263	0.01%	289
2022 Q4	$319K	Buy	244,482 +150	+0.1%	+$165	0.01%	319
2022 Q3	$256K	Hold	244,332	–	–	﹤0.01%	335
2022 Q2	$264K	Hold	244,332	–	–	﹤0.01%	310
2022 Q1	$257K	Buy	+244,332	New	+$224K	﹤0.01%	353
2021 Q4	–	Sell	-244,332	Closed	-$325K	–	405
2021 Q3	$325K	Hold	244,332	–	–	0.01%	346
2021 Q2	$467K	Buy	+244,332	New	+$841K	0.01%	318
2019 Q4	–	Sell	-6,136	Closed	-$13K	–	466
2019 Q3	$13K	Sell	6,136 -6,570	-52%	-$19.6K	﹤0.01%	439
2019 Q2	$60K	Hold	12,706	–	–	﹤0.01%	425
2019 Q1	$55K	Hold	12,706	–	–	﹤0.01%	383
2018 Q4	$39K	Hold	12,706	–	–	﹤0.01%	331
2018 Q3	$91K	Buy	12,706 +6,570	+107%	+$33K	﹤0.01%	432
2018 Q2	$28K	Sell	6,136 -6,570	-52%	-$29.2K	﹤0.01%	420
2018 Q1	$68K	Hold	12,706	–	–	﹤0.01%	329
2017 Q4	$85K	Buy	+12,706	New	+$85.7K	0.01%	199

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Meitav Investment House's PLX Position: Q2 2023 in Review

Meitav Investment House sold out of Protalix BioTherapeutics (PLX) in Q2 2023, closing a stake of 244,332 shares — an estimated $494K sold.

Meitav Investment House first reported a position in PLX in Q4 2017 and held it in 15 quarters. The position peaked at $494K in Q1 2023. 66 funds tracked by Wall St. Rank hold PLX as of Q2 2023.

Meitav Investment House reported no remaining Protalix BioTherapeutics position as of Q2 2023 after selling out during the quarter.
Meitav Investment House sold 244,332 Protalix BioTherapeutics shares in Q2 2023, an estimated $494K.
Meitav Investment House first reported a position in Protalix BioTherapeutics in Q4 2017 and held it in 15 quarters.
Meitav Investment House's Protalix BioTherapeutics position peaked at $494K in Q1 2023.
66 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q2 2023.

Based on Meitav Investment House's 13F filing for Q2 2023, filed 24 Jul 2023.